Will the Phase 2 trial "Safety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectable Hepatocellular Carcinoma" reach primary completion on or before Mar 31, 2028?

Resolves Yes if ClinicalTrials.gov record NCT06911255 (Yoon Jun Kim) shows an actual primary completion date on or before Mar 31, 2028. Registered date at generation: Mar 31, 2028.

Outcome verified from clinicaltrials.gov.

1. Market open

   Jul 17, 2026, 7:40 AM UTC
2. Market closes

   By Mar 31, 2028, 11:59 PM UTC
3. Projected payout

   Shortly after the market closes

Trading on material non-public information is prohibited. Markets are for entertainment and informational purposes using free Pulse Credits — no real-money wagering. If you believe a participant has acted on inside information, please report it.